Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Novel Antigens LMA and Kma Are Expressed on Malignant Bone Marrow Plasma Cells from Patients with Relapsed Refractory Multiple Myeloma and Plasma Cell Dyscrasias

Mary Sartor, David J Gottlieb, Rosanne Dunn

Blood (2022) 140 (Supplement 1): 4211–4212.

https://doi.org/10.1182/blood-2022-167427

Published: 2022

Journal Articles

A Novel B Cell Antigen Designated Lambda Myeloma Antigen (LMA) Has Been Identified Using Two Fully Human Monoclonal Antibodies (Mabs) That Bind to Similar Epitopes on Plasma Cells from Patients with Plasma Cell Dyscrasias

Mary Sartor, Daniel Y Hu, Thomas X Lemarchand, Luise Britz, Rosanne Dunn, David J Gottlieb

Blood (2021) 138 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2021-148243

Published: 2021

Journal Articles

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Flora Yuen, BBiomedSc, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Patricia Walker, MBBS, BMedSci, FRACP, FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Rosanne Dunn, PhD, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3144.

https://doi.org/10.1182/blood-2019-130084

Published: 2019

Journal Articles

The Anti-Kappa Monoclonal Antibody MDX-1097 Synergizes with Immunomodulatory Drugs to Enhance Antibody-Dependent Cell Cytotoxicity of Multiple Myeloma Cells

Andrew R Cuddihy, PhD, Parisa Asvadi, PhD, Rosanne Dunn, PhD, Tiffany T. Khong, BSc, PhD, Andrew Spencer, MD

Blood (2012) 120 (21): 4012.

https://doi.org/10.1182/blood.V120.21.4012.4012

Published: 2012

Journal Articles

MDX-1097 Binds Specifically to Kappa Myeloma Cells and Anti-Tumour Activity Is Mediated by Multiple Effector Cells.

Mae Wong, PhD, Parisa Asvadi, PhD, Rosanne Dunn, PhD, Darren Jones, Douglas Campbell, PhD, Andrew Spencer, DM

Blood (2009) 114 (22): 1846.

https://doi.org/10.1182/blood.V114.22.1846.1846

Published: 2009

NARROW

Novel Antigens LMA and Kma Are Expressed on Malignant Bone Marrow Plasma Cells from Patients with Relapsed Refractory Multiple Myeloma and Plasma Cell Dyscrasias

A Novel B Cell Antigen Designated Lambda Myeloma Antigen (LMA) Has Been Identified Using Two Fully Human Monoclonal Antibodies (Mabs) That Bind to Similar Epitopes on Plasma Cells from Patients with Plasma Cell Dyscrasias

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

The Anti-Kappa Monoclonal Antibody MDX-1097 Synergizes with Immunomodulatory Drugs to Enhance Antibody-Dependent Cell Cytotoxicity of Multiple Myeloma Cells

MDX-1097 Binds Specifically to Kappa Myeloma Cells and Anti-Tumour Activity Is Mediated by Multiple Effector Cells.

Email alerts

ASH Publications

American Society of Hematology

Novel Antigens LMA and Kma Are Expressed on Malignant Bone Marrow Plasma Cells from Patients with Relapsed Refractory Multiple Myeloma and Plasma Cell Dyscrasias

A Novel B Cell Antigen Designated Lambda Myeloma Antigen (LMA) Has Been Identified Using Two Fully Human Monoclonal Antibodies (Mabs) That Bind to Similar Epitopes on Plasma Cells from Patients with Plasma Cell Dyscrasias

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

The Anti-Kappa Monoclonal Antibody MDX-1097 Synergizes with Immunomodulatory Drugs to Enhance Antibody-Dependent Cell Cytotoxicity of Multiple Myeloma Cells

MDX-1097 Binds Specifically to Kappa Myeloma Cells and Anti-Tumour Activity Is Mediated by Multiple Effector Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only